MENU
Showcases Stock ranks Forex

Apellis Pharmaceuticals Inc (APLS)
58.78  0.29 (0.5%) 03-28 16:00
Open: 58.47 Pre. Close: 58.49
High: 58.955 Low: 56.82
Volume: 1,218,295 Market Cap: 7,088(M)
Stock Technical Analysis
Overall:     
Target: Six months: 75.63
One year: 83.98
Support: Support1: 53.19
Support2: 44.25
Resistance: Resistance1: 64.75
Resistance2: 71.90
Pivot: 57.59
Moving Averages: MA(5): 57.44
MA(20): 58.91
MA(100): 59.98
MA(250): 61.07
MACD: MACD(12,26): -1.85
Signal(12,26,9): -2.14
%K %D: %K(14,3): 52.94
%D(3): 41.48
RSI: RSI(14): 46.31
52-Week: High: 94.75
Low: 19.83
Change(%): -11.0
Average Vol(K): 3-Month: 1573
10-Days: 1102
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 59.003 - 59.283 59.283 - 59.545
Low: 56.11 - 56.429 56.429 - 56.729
Close: 58.249 - 58.757 58.757 - 59.234
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ APLS ] has closed below upper band by 33.7%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Stock chart
Stock News
Thu, 28 Mar 2024
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Is Breakeven Near? - Simply Wall St

Thu, 28 Mar 2024
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Thu, 28 Mar 2024
Apellis Pharmaceuticals (NASDAQ:APLS) Given Neutral Rating at Mizuho - Defense World

Wed, 27 Mar 2024
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals | Markets Insider - Markets Insider

Tue, 26 Mar 2024
Whittier Trust Co. Buys Shares of 3700 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Thu, 14 Mar 2024
Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares - Yahoo Finance

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Underperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 120.58
Shares Float (M) 81.05
% Held by Insiders 13.23
% Held by Institutions 95.96
Shares Short (K) 10060
Shares Short Prior Month (K) 10670
Stock Financials
EPS -4.450
Book Value (p.s.) 1.630
Profit Margin -133.29
Operating Margin -57.74
Return on Assets (ttm) -41.7
Return on Equity (ttm) -290.1
Qtrly Rev. Growth 545.9
Gross Profit (p.s.)
Sales Per Share 3.289
EBITDA (p.s.) -4.274
Qtrly Earnings Growth
Operating Cash Flow (M) -594.73
Levered Free Cash Flow (M) -404.84
Stock Valuation
PE Ratio -13.21
PEG Ratio -1.42
Price to Book value 36.06
Price to Sales 17.87
Price to Cash Flow -11.92
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android